Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2026 | GALAXY: ctDNA dynamics and adjuvant chemotherapy in colorectal cancer

Erika Ruiz-Garcia, MD, Instituto Nacional de Cancerologia, Mexico City, Mexico, comments on findings from the GALAXY study (UMIN00039205), which analyzed circulating tumor DNA (ctDNA) dynamics at two post-surgical timepoints to identify patients with resected stage I–IV colorectal cancer (CRC) who may benefit from adjuvant chemotherapy. The results support ctDNA dynamics as a tool for treatment decision-making in this setting. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

That’s a very nice study from the Japanese community, but it’s an observational study. So that means that the results cannot be applied instantly to the community. But we have to say that they want to check how the ctDNA works in the prognostic and predictive way. So they find out the data that they have is that supports that ctDNA is a good biomarker in the prognostic way, but not in the predictive way...

That’s a very nice study from the Japanese community, but it’s an observational study. So that means that the results cannot be applied instantly to the community. But we have to say that they want to check how the ctDNA works in the prognostic and predictive way. So they find out the data that they have is that supports that ctDNA is a good biomarker in the prognostic way, but not in the predictive way. So it needs more trials to figure out how can ctDNA help us to escalate or deescalate a treatment.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...